How are XENE covered call max profit and max loss calculated?

Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium. For the XENE covered call priced from the end-of-day chain at a 30-day expiry (ATM IV 42.90%), the computed maximum profit is $628.50 per contract and the computed maximum loss is -$5,120.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a XENE covered call?

The breakeven for the XENE covered call priced on this page is roughly $51.21 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current XENE market-implied 1-standard-deviation expected move is approximately 12.30%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current XENE implied volatility affect this covered call?

XENE ATM IV is at 42.90% with IV rank near 5.83%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

XENE Covered Call Strategy

XENE (Xenon Pharmaceuticals Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

XENE (Xenon Pharmaceuticals Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $4.41B, a beta of 0.65 versus the broader market, a 52-week range of 28.19-63.95, average daily share volume of 1.4M, a public-listing history dating back to 2014, approximately 316 full-time employees. These structural characteristics shape how XENE stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.65 indicates XENE has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a covered call on XENE?

A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income.

Current XENE snapshot

As of May 15, 2026, spot at $54.39, ATM IV 42.90%, IV rank 5.83%, expected move 12.30%. The covered call on XENE below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 63-day expiry.

Why this covered call structure on XENE specifically: XENE IV at 42.90% is on the cheap side of its 1-year range, which means a premium-selling XENE covered call collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 12.30% (roughly $6.69 on the underlying). The 63-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated XENE expiries trade a higher absolute premium for lower per-day decay. Position sizing on XENE should anchor to the underlying notional of $54.39 per share and to the trader's directional view on XENE stock.

XENE covered call setup

The XENE covered call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With XENE near $54.39, the first option leg uses a $57.50 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed XENE chain at a 63-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 XENE shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 100 shares	Stock	$54.39	long
Sell 1	Call	$57.50	$3.18

XENE covered call risk and reward

Net Premium / Debit: -$5,121.50
Max Profit (per contract): $628.50
Max Loss (per contract): -$5,120.50
Breakeven(s): $51.21
Risk / Reward Ratio: 0.123

Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium.

XENE covered call payoff curve

Modeled P&L at expiration across a range of underlying prices for the covered call on XENE. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	-$5,120.50
$12.03	-77.9%	-$3,918.02
$24.06	-55.8%	-$2,715.54
$36.08	-33.7%	-$1,513.05
$48.11	-11.5%	-$310.57
$60.13	+10.6%	+$628.50
$72.16	+32.7%	+$628.50
$84.18	+54.8%	+$628.50
$96.21	+76.9%	+$628.50
$108.23	+99.0%	+$628.50

When traders use covered call on XENE

Covered calls on XENE are an income strategy run on existing XENE stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.

XENE thesis for this covered call

The market-implied 1-standard-deviation range for XENE extends from approximately $47.70 on the downside to $61.08 on the upside. A XENE covered call collects premium on an existing long XENE position, trading off upside above the short call strike for immediate income; the short strike selection should reflect the trader's view on whether XENE will breach that level within the expiration window. Current XENE IV rank near 5.83% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on XENE at 42.90%. As a Healthcare name, XENE options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to XENE-specific events.

XENE covered call positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. XENE positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move XENE alongside the broader basket even when XENE-specific fundamentals are unchanged. Short-premium structures like a covered call on XENE carry tail risk when realized volatility exceeds the implied move; review historical XENE earnings reactions and macro stress periods before sizing. Always rebuild the position from current XENE chain quotes before placing a trade.

Frequently asked questions

What is a covered call on XENE?: A covered call on XENE is the covered call strategy applied to XENE (stock). The strategy is structurally neutral to slightly bullish: A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income. With XENE stock trading near $54.39, the strikes shown on this page are snapped to the nearest listed XENE chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are XENE covered call max profit and max loss calculated?: Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium. For the XENE covered call priced from the end-of-day chain at a 30-day expiry (ATM IV 42.90%), the computed maximum profit is $628.50 per contract and the computed maximum loss is -$5,120.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a XENE covered call?: The breakeven for the XENE covered call priced on this page is roughly $51.21 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current XENE market-implied 1-standard-deviation expected move is approximately 12.30%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a covered call on XENE?: Covered calls on XENE are an income strategy run on existing XENE stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
How does current XENE implied volatility affect this covered call?: XENE ATM IV is at 42.90% with IV rank near 5.83%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.